FCF Pharmaceutical Market Study – 2020 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Pharmaceutical Market Study – 2020”.

Based on available data from European pharmaceutical providers, the FCF Pharmaceutical Market Study is a detailed and comprehensive analysis of the pharmaceutical sector and especially addresses the European small- / midcap market segment.

Key findings of the FCF Pharmaceutical Market Study (September 2020):

  • Revenue is expected to increase by +0.3% from ’19 to ’20
  • EBITDA is expected to increase by +2.6% from ’19 to ’20
  • EBIT is expected to decrease by -10.8% from ’19 to ’20
  • EV / EBITDA valuation multiple slightly decreased from 12.2x in ’19 to 12.0x LTM
  • Net leverage decreased from 2.1x in ’19 to 1.9x LTM
  • Interest cover ratio increased from 57.5x in ’19 to 67.2x LTM
  • The number of Private Equity (PE) deals increased from 30 in ’18 to 37 in ’19 and M&A deal activity decreased from 40 in ’18 to 33 in ‘19

To access the full report, please click here.

By Marcel Lange, Tristan Blümli, Marco Buonafede and Yasmin Herrmann

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]